Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: In silico epitope mapping and experimental evaluation of the Merozoite Adhesive Erythrocytic Binding Protein (MAEBL) as a malaria vaccine candidate
Authors: Pedro Cravo
Renato B. Machado
Juliana A. Leite
Taizy Leda
Rossarin Suwanarusk
Najara Bittencourt
Letusa Albrecht
Carla Judice
Stefanie C.P. Lopes
Marcus V.G. Lacerda
Marcelo U. Ferreira
Irene S. Soares
Yun Shan Goh
Daniel Y. Bargieri
François Nosten
Bruce Russell
Laurent Rénia
Fabio T.M. Costa
A-Star, Singapore Immunology Network
Fundacao de Medicina Tropical do Amazonas
Universidade Nova de Lisboa, Instituto de Higiene e Medicina Tropical
Universidade Estadual de Campinas
Universidade Federal de Goias
Fundacao Oswaldo Cruz
National University of Singapore
Mahidol University
Nuffield Department of Clinical Medicine
Universidade de Sao Paulo - USP
Keywords: Immunology and Microbiology;Medicine
Issue Date: 10-Jan-2018
Citation: Malaria Journal. Vol.17, No.1 (2018)
Abstract: © 2018 The Author(s). Background: Technical limitations for culturing the human malaria parasite Plasmodium vivax have impaired the discovery of vaccine candidates, challenging the malaria eradication agenda. The immunogenicity of the M2 domain of the Merozoite Adhesive Erythrocytic Binding Protein (MAEBL) antigen cloned from the Plasmodium yoelii murine parasite, has been previously demonstrated. Results: Detailed epitope mapping of MAEBL through immunoinformatics identified several MHCI, MHCII and B cell epitopes throughout the peptide, with several of these lying in the M2 domain and being conserved between P. vivax, P. yoelii and Plasmodium falciparum, hinting that the M2-MAEBL is pan-reactive. This hypothesis was tested through functional assays, showing that P. yoelii M2-MAEBL antisera are able to recognize and inhibit erythrocyte invasion from both P. falciparum and P. vivax parasites isolated from Thai patients, in ex vivo assays. Moreover, the sequence of the M2-MAEBL is shown to be highly conserved between P. vivax isolates from the Amazon and Thailand, indicating that the MAEBL antigen may constitute a vaccine candidate outwitting strain-specific immunity. Conclusions: The MAEBL antigen is promising candidate towards the development of a malaria vaccine.
ISSN: 14752875
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.